Home > In process > Dementia risk factor assessment in a local Alzheimer's prevention population: a German cross-sectional, observational study. > print

001     286091
005     20260413130401.0
024 7 _ |a 10.1016/j.tjpad.2026.100556
|2 doi
024 7 _ |a pmid:41935406
|2 pmid
024 7 _ |a 2274-5807
|2 ISSN
024 7 _ |a 2426-0266
|2 ISSN
037 _ _ |a DZNE-2026-00387
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sannemann, Lena
|b 0
245 _ _ |a Dementia risk factor assessment in a local Alzheimer's prevention population: a German cross-sectional, observational study.
260 _ _ |a [Paris]
|c 2026
|b Elsevier Masson SAS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1776077933_32198
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The risk for dementia is to a significant extent driven by potentially modifiable factors. Prevention strategies are increasingly aiming at individually tailored risk reduction approaches, particularly in light of emerging Brain Health Services for dementia prevention (dBHS).The cross-sectional observational study 'Individual Risk Profiling for Alzheimer's and Dementia Prevention' (INSPIRATION) assessed the individual risk factors of 162 participants of the local Cologne Alzheimer Prevention Registry and provided individual feedback on risk profiles during a single visit. We analysed the frequency and patterns of risk factors and explored their association with cognition and Alzheimer's disease (AD) plasma biomarkers.The most common risk factors in this population were obesity, non-adherence to a Mediterranean diet, low subjective sleep quality, subjective experience of stress, and hearing impairment. A principal component analysis (PCA) revealed six principal components (PC), which we labeled as (1) psychosocial factors, (2) blood pressure, (3) physical condition, (4) hearing impairment, (5) lifestyle, and (6) substance use. We found isolated associations between PCs, cognition, and AD plasma biomarkers.These findings provide initial insights into which risk factors may be most relevant and actionable for highly-educated and prevention-motivated populations likely to seek dBHS. Interventions addressing the domains of psychosocial factors, physical condition, and lifestyle may be particularly relevant to consider for a personally tailored risk reduction approach in comparable populations.The study was funded by research funds of the Medical Faculty and the University Hospital Cologne, University of Cologne and the non-profit association Kölner Verein für seelische Gesundheit e.V.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Dementia
|2 Other
650 _ 7 |a Modifiable risk factors
|2 Other
650 _ 7 |a Prevention
|2 Other
650 _ 7 |a Risk assessment
|2 Other
650 _ 7 |a Risk communication
|2 Other
700 1 _ |a Gerards, Michelle
|0 P:(DE-2719)9003021
|b 1
|u dzne
700 1 _ |a Bohr, Lara
|b 2
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 3
|u dzne
700 1 _ |a Escher, Claus
|0 P:(DE-2719)9002022
|b 4
|u dzne
700 1 _ |a Kalthegener, Franziska
|b 5
700 1 _ |a Müller, Theresa
|b 6
700 1 _ |a Ramírez, Alfredo
|0 P:(DE-2719)2812825
|b 7
|u dzne
700 1 _ |a Zeyen, Philip
|b 8
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 9
|u dzne
700 1 _ |a Rostamzadeh, Ayda
|b 10
773 _ _ |a 10.1016/j.tjpad.2026.100556
|g Vol. 13, no. 6, p. 100556 -
|0 PERI:(DE-600)2782183-3
|n 6
|p 100556
|t The journal of prevention of Alzheimer's disease
|v 13
|y 2026
|x 2274-5807
856 4 _ |u https://pub.dzne.de/record/286091/files/DZNE-2026-00387.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/286091/files/DZNE-2026-00387.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9003021
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9002022
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-05-28T09:11:42Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-05-28T09:11:42Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-05-28T09:11:42Z
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka
|l Neuroinflammation, Biomarker
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 1
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 2
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 3
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21